S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
NASDAQ:BLUE

bluebird bio - BLUE Stock Forecast, Price & News

$8.49
+0.88 (+11.56%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.40
$8.50
50-Day Range
$5.16
$8.49
52-Week Range
$2.87
$11.70
Volume
5.60 million shs
Average Volume
3.68 million shs
Market Capitalization
$703.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.88

bluebird bio MarketRank™ Forecast

Analyst Rating
Hold
1.89 Rating Score
Upside/​Downside
19.0% Downside
$6.88 Price Target
Short Interest
Healthy
23.24% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.69mentions of bluebird bio in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$9,493 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.27) to ($2.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

959th out of 1,034 stocks

Biological Products, Except Diagnostic Industry

163rd out of 171 stocks

BLUE stock logo

About bluebird bio (NASDAQ:BLUE) Stock

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

BLUE Stock News Headlines

Why CSL Ltd Stock Could Be Worth a Look (BLUE)
FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment.
bluebird bio (NASDAQ:BLUE) Stock Price Up 6.3%
2 Growth Stocks That Could Double in 2023
Recap: bluebird bio Q3 Earnings
bluebird bio: Commercial Success Highly Uncertain
bluebird bio, Inc. (BLUE)
Should You Buy the Dip With Bluebird Bio?
Why Bluebird Bio Stock Is Taking Flight Today
Is This Growth Stock Undervalued?
See More Headlines
Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

BLUE Company Calendar

Last Earnings
11/05/2021
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/03/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLUE
Fax
N/A
Employees
518
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.88
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
-19.0%
Consensus Rating
Hold
Rating Score (0-4)
1.89
Research Coverage
9 Analysts

Profitability

Net Income
$-819,380,000.00
Net Margins
-8,828.28%
Pretax Margin
-8,384.38%

Debt

Sales & Book Value

Annual Sales
$3.66 million
Book Value
$1.92 per share

Miscellaneous

Free Float
80,506,000
Market Cap
$703.91 million
Optionable
Optionable
Beta
0.98

Key Executives

  • Mr. Andrew  ObenshainMr. Andrew Obenshain (Age 47)
    Pres, CEO & Director
    Comp: $842.85k
  • Mr. Thomas J. Klima (Age 50)
    Chief Commercial Officer & COO
    Comp: $509.7k
  • Mr. Christopher Krawtschuk CPA (Age 48)
    CFO, Principal Accounting Officer & Treasurer
  • Ms. Elizabeth Pingpank
    Director of Corp. Communications
  • Sarah Alspach
    Chief Communications Officer
  • Ms. Andrea Walton
    Chief People Officer
  • Dr. Liviu Niculescu M.D.
    Ph.D., Sr. VP of Global Medical Affairs
  • Ms. Melissa Bonner
    Sr. VP of Research
  • Mr. Richard Colvin M.D.
    Ph.D., Chief Medical Officer
  • Mr. Kasra Kasraian
    Sr. VP of Technical Devel. & Operations













BLUE Stock - Frequently Asked Questions

Should I buy or sell bluebird bio stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 2 sell ratings, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings
or view top-rated stocks.

What is bluebird bio's stock price forecast for 2023?

9 equities research analysts have issued 1-year target prices for bluebird bio's shares. Their BLUE share price forecasts range from $3.00 to $10.00. On average, they predict the company's share price to reach $6.88 in the next twelve months. This suggests that the stock has a possible downside of 19.0%.
View analysts price targets for BLUE
or view top-rated stocks among Wall Street analysts.

How have BLUE shares performed in 2022?

bluebird bio's stock was trading at $9.99 at the beginning of the year. Since then, BLUE stock has decreased by 15.0% and is now trading at $8.49.
View the best growth stocks for 2022 here
.

Are investors shorting bluebird bio?

bluebird bio saw a decrease in short interest in November. As of November 15th, there was short interest totaling 19,270,000 shares, a decrease of 14.5% from the October 31st total of 22,540,000 shares. Based on an average daily trading volume, of 6,040,000 shares, the days-to-cover ratio is presently 3.2 days.
View bluebird bio's Short Interest
.

When is bluebird bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 3rd 2023.
View our BLUE earnings forecast
.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) posted its earnings results on Friday, November, 5th. The biotechnology company reported ($3.16) EPS for the quarter, missing analysts' consensus estimates of ($2.65) by $0.51. The biotechnology company had revenue of $22.70 million for the quarter, compared to analyst estimates of $39.07 million. bluebird bio had a negative net margin of 8,828.28% and a negative trailing twelve-month return on equity of 173.58%. The business's quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($2.94) earnings per share.

What is Nick Leschly's approval rating as bluebird bio's CEO?

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (15.34%), BlackRock Inc. (8.32%), Tang Capital Management LLC (7.64%), Vanguard Group Inc. (4.47%), Credit Suisse AG (1.91%) and Dimensional Fund Advisors LP (1.96%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Philip D Gregory, Richard A Colvin, Thomas J Klima and William D Baird III.
View institutional ownership trends
.

How do I buy shares of bluebird bio?

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $8.49.

How much money does bluebird bio make?

bluebird bio (NASDAQ:BLUE) has a market capitalization of $703.91 million and generates $3.66 million in revenue each year. The biotechnology company earns $-819,380,000.00 in net income (profit) each year or ($6.10) on an earnings per share basis.

How many employees does bluebird bio have?

The company employs 518 workers across the globe.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com.

This page (NASDAQ:BLUE) was last updated on 12/3/2022 by MarketBeat.com Staff